Amino acid losses during hemodialysis with infusion of amino acids and glucose

Amino acid losses during hemodialysis with infusion of amino acids and glucose. This study evaluated the effects during hemodialysis of intravenous infusion of amino acids and glucose on plasma amino acid and glucose concentrations and amino acid losses. Eight men undergoing maintenance hemodialysis were each studied during two dialyses using glucose-free dialysate. During one hemodialysis, they were infused with 800ml of normal saline. During the other hemodialysis, they were infused with an equal volume of water which contained 39.5g of essential and non-essential free L-amino acids and 200g of d-glucose. The solutions were infused throughout the dialysis procedure into the drip chamber of the venous outflow from the dialyzer. Subjects were fasted from the night before until the end of hemodialysis, and the order of administration of the two solutions was determined randomly. Plasma essential, non-essential, and total amino acids fell significantly during the infusion of normal saline and rose during the administration of amino acids and glucose. Dialysate total-free amino acid losses averaged 8.2 ± 3.1SDg during the infusion of normal saline and 12.6 ± 3.6g with the administration of amino acids and glucose. These findings indicate that the intravenous infusion of amino acids and glucose during hemodialysis prevents a fall in plasma amino acid and glucose concentrations and leads to only a slight increase in the losses of free amino acids into dialysate. Because most of the infused amino acids are retained, this technique may be used during hemodialysis to avoid a net outflow of amino acids, minimize disruption of amino acid and glucose pools, and provide a nutritional supplement.Pertes en amino-acides au cours de l'hémodialyse avec perfusion d'acides aminés et de glucose. Cette étude a permis d'évaluer les effets de la perfusion intraveineuse d'acides aminés et de glucose pendant l'hémodialyse sur les concentrations plasmatiques d'acides aminés et de glucose, et les pertes d'acides aminés. Huit hommes en hémodialyse chronique ont chacun été étudiés pendant deux dialyses avec un dialysat sans glucose. Pendant une des dialyses ils étaient perfusés avec 800ml de soluté physiologique. Pendant l'hemodialyse autre ils ont infusé avec un égal volume d'eau contenant 39,5g de L-acides aminés libres essentiels ou non, et 200g de d-glucose. Les solutions étaient perfusées pendant la dialyse dans la tubulure veineuse venant du dialyseur. Les malades étaient à jeûn la nuit précédante et jusqu'à la fin de la dialyse, et l'ordre d'administration des deux solutions était déterminé au hasard. Les acides aminés plasmatiques totaux, essentiels et non essentiels ont significativement diminué pendant la perfusion de soluté physiologique, et se sont élevés pendant l'administration d'acides aminés et de glucose. Dans le dialysat, les pertes totales d'acides aminés libres étaient en moyenne de 8,2 ± 3,1g (ds) pendant la perfusion de soluté physiologique, et de 12,6 ± 3,6g lors de l'administration d'acides aminés et de glucose. Ces résultats indiquent que la perfusion intraveineuse d'acides aminés et de glucose au cours de la dialyse empêche la chute des acides aminés et du glucose plasmatiques et n'occasionne qu'une diminution minime des pertes en acides aminés libres dans le dialysat. Puisque la plupart des acides aminés perfusés est retenue, cette technique pourrait être utilisée pendant l'hémodialyse pour éviter une fuite nette d'acides aminés, pour minimiser la dissipation des réserves d'acides aminés et de glucose et pour apporter un supplément nutritif

Risks of chronic metabolic acidosis in patients with chronic kidney disease

Risks of chronic metabolic acidosis in patients with chronic kidney disease Metabolic acidosis is associated with chronic renal failure (CRF). Often, maintenance dialysis therapies are not able to reverse this condition. The major systemic consequences of chronic metabolic acidosis are increased protein catabolism, decreased protein synthesis, and a negative protein balance that improves after bicarbonate supplementation. Metabolic acidosis also induces insulin resistance and a decrease in the elevated serum leptin levels associated with CRF. These three factors may promote protein catabolism in maintenance dialysis patients. Available data suggest that metabolic acidosis is both catabolic and anti-anabolic. Several clinical studies have shown that correction of metabolic acidosis in maintenance dialysis patients is associated with modest improvements in nutritional status. Preliminary evidence indicates that metabolic acidosis may play a role in β2-microglobulin accumulation, as well as the hypertriglyceridemia seen in renal failure. Interventional studies for metabolic acidosis have yielded inconsistent results in CRF and maintenance hemodialysis patients. In chronic peritoneal dialysis patients, the mitigation of acidemia appears more consistently to improve nutritional status and reduce hospitalizations. Large-scale, prospective, randomized interventional studies are needed to ascertain the potential benefits of correcting acidemia in maintenance hemodialysis patients. To avoid adverse events, an aggressive management approach is necessary to correct metabolic acidosis. Clinicians should attempt to adhere to the National Kidney Foundation Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines for maintenance dialysis patients. The guidelines recommend maintenance of serum bicarbonate levels at 22 mEq/L or greater

Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis

Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Balance studies for nitrogen, potassium, magnesium, phosphorus, and calcium were carried out in eight men undergoing continuous ambulatory peritoneal dialysis (CAPD) to determine dietary protein requirements and mineral balances. Patients were fed high energy diets for 14 to 33 days which provided either 0.98 (seven studies) or 1.44g (six studies) of primarily high biological value protein/kg body wt/day. Mean nitrogen balance was neutral with the lower protein diet (+0.35 ± 0.83SEMg/day) and strongly positive with the higher protein diet (+2.94 ± 0.54g/day). With the higher protein diet the balances for potassium, magnesium, and phosphorus were strikingly positive, there was an increase in body weight in all patients, and a rise in mid-arm muscle circumference in five of the six patients. The relation between protein intake and nitrogen balance suggests that the daily protein requirement for clinically stable CAPD patients should be at least 1.1g/kg/day; to account for variability among subjects 1.2 to 1.3g protein/kg/day is probably preferable. Potassium balance correlated directly with nitrogen balance (r = 0.81). High fecal potassium losses (19 ± 1.2 mEq/day) in all patients probably helped maintain normal serum potassium concentrations. Mean serum magnesium was increased (3.1 ± 0.1 mg/dl), and magnesium balances were positive suggesting that the dialysate magnesium of 1.85 mg/dl is excessive. The netgain of calcium from dialysate was 84 ± 18 mg/day; this correlated inversely with serum calcium levels (r = -0.90).Bilans métaboliques et besoins protéiques alimentaires de malades en dialyse péritonéale continue ambulatoire. Des études de bilan de l'azote, du potassium, du magnésium, du phosphore et du calcium, étaient fait en sept hommes en dialyse péritonéale continue ambulatoire (CAPD), pour déterminer leurs besoins protéiques alimentaires et leur bilan minéral. Les malades ont reçu pendant 14 à 33 jours des régimes hautement énergétiques, apportant soit 0,98 (sept études), soit 1,44g (six études) de protéines de haute valeur biologique par kg de poids et par jour. Le bilan azoté moyen etait nul avec le régime comportant la plus faibie teneur protéique (+ 0,35 ± 0,88g/jSEM) et était fortement positive avec le régime à plus forte teneur protéique (+2,94 ± 0,54g/j). Avec le régime à haute teneur en protéine, les bilans potassique, magnésien et phosphoré étaient fortement positifs; le poids corporel s'est élevé chez tous les malades; la circonférence musculaire mesurée du milieu du bras a augmenté chez cinq sur six malades. La relation existant entre l'apport protéique et le bilan azoté suggère que les besoins journaliers en protéines pour des malades cliniquement stables en CAPD devraient être au moins de 1,1g/kg/j; 1,2 à 1,3g de protéines/kg/j sont sans doute préférables pour tenir compte de la variabilité entre les sujets. Le bilan potassique était directement corrélé avec la balance azotée (r = 0,81). De fortes pertes potassiques fécales (19 ± 1,2 mEq/j) chez tous les malades ont probablement contribué à maintenir normales les concentrations sériques du potassium. La magnésémie moyenne était élevée (3,1 ± 0,1 mg/dl), et les bilans magnésiens aient positifs suggérant que le magnésium du dialysat (1,85 18 mg/dl) était trop élevé. Le gain net en calcium à partir du dialysat était de 84 ± 18 mg/j; ce gain était inversement corrélé avec la calcémie (r = 0,90)

Glucose absorption during continuous ambulatory peritoneal dialysis

Glucose absorption during continuous ambulatory peritoneal dialysis. Patients undergoing continuous ambulatory peritoneal dialysis (CAPD) are exposed to a continuous infusion of glucose via their peritoneal cavity. We performed studies to quantitate the amount of energy derived from dialysate glucose. Net glucose absorption averaged 182 ± (SD) 61 g/day in 19 studies with a dialysate dextrose concentration of 1.5 or 4.25 g/dl. The amount of glucose absorbed per liter of dialysate (y) varied with the concentration of glucose in dialysate (x), (y = 11.3x - 10.9, r = 0.96), The amount of glucose absorbed per day during a given dialysis regimen was constant. Energy intake from dialysate glucose was 8.4 ± 2.8 kcal/kg of body wt per day, or 12 to 34% of total energy intake. This additional energy may contribute to the anabolic effect reported during CAPD. The ability to vary glucose absorption by altering the dialysate glucose concentration may prove a useful tool to modify energy intake.Absorption de glucose au cours de la dialyse péritonéale continue ambulatoire. Les malades soumis à la dialyse péritonéale continue ambulatoire (CAPD) sont exposés à une administration continue de glucose via leur cavité péritonéale. La quantité d'énergie qui dérive du glucose du dialysat a été quantifiée. L'absorption nette de glucose est en moyenne de 182 ± (SD) 61 g/jour au cours de 19 études avec un dialysat contenant du dextrose, 1,5 ou 4,25 g/dl. La quantité de glucose absorbée par litre de dialysat (y) varie avec la concentration de glucose dans le dialysat (x), (y = 11,3x - 10,9, r = 0,96). La quantité de glucose absorbée par jour pour un type donné de dialyse a été constante. L'entrée d'énergie à partir du glucose du dialysat était de 8,4 ± 2,8 kcal/kg de poids par jour, soit 12 à 34% de l'entrée totale d'énergie. Cette énergie supplémentaire peut contribuer à l'effet anabolique rapporté au cours de CAPD. La possibilité de faire varier l'absorption de glucose en modifiant la concentration de glucose dans le dialysat peut être un moyen utile pour influencer l'entrée d'énergie

Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study

Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. The safety of dietary protein and phosphorous restriction was evaluated in the Modification of Diet in Renal Disease (MDRD) Study. In Study A, 585 patients with a glomerular filtration rate (GFR) of 25 to 55 ml/min/1.73m2 were randomly assigned to a usual-protein diet (1.3 g/kg/day) or a low-protein diet (0.58 g/kg/day). In Study B, 255 patients with a GFR of 13 to 24 ml/min/1.73m2 were randomly assigned to the low-protein diet or a very-low-protein diet (0.28 g/kg/day), supplemented with a ketoacid-amino acid mixture (0.28 g/kg/day). The low-protein and very-low-protein diets were also low in phosphorus. Mean duration of follow-up was 2.2 years in both studies. Protein and energy intakes were lower in the low-protein and very-low-protein diet groups than in the usual-protein group. Two patients in Study B reached a “stop point” for malnutrition. There was no difference between randomized groups in the rates of death, first hospitalizations, or other “stop points” in either study. Mean values for various indices of nutritional status remained within the normal range during follow-up in each diet group. However, there were small but significant changes from baseline in some nutritional indices, and differences between the randomized groups in some of these changes. In the low-protein and very-low-protein diet groups, serum albumin rose, while serum transferrin, body wt, percent body fat, arm muscle area and urine creatinine excretion declined. Combining patients in both diet groups in each study, a lower achieved protein intake (from food and supplement) was not correlated with a higher rate of death, hospitalization or stop points, or with a progressive decline in any of the indices of nutritional status after controlling for baseline nutritional status and follow-up energy intake. These analyses suggest that the low-protein and very-low-protein diets used in the MDRD Study are safe for periods of two to three years. Nonetheless, both protein and energy intake declined and there were small but significant declines in various indices of nutritional status. These declines are of concern because of the adverse effect of protein calorie malnutrition in patients with end-stage renal disease. Physicians who prescribe low-protein diets must carefully monitor patients' protein and energy intake and nutritional status

Dietary Protein Intake and Survival in 100,088 Maintenance Hemodialysis Patients: The Role of Race and Albumin

Decreased dietary protein intake may be associated with increased mortality risk in individuals undergoing maintenance hemodialysis (MHD). We examined 8−year all-cause mortality in 100,088 MHD patients from DaVita dialysis clinics in the US (2001–2009) and hypothesized that survival is better across higher levels of nPNA, (nPCR, a dietary protein intake surrogate) with consistent trends across race and in hypoalbuminemic patients. Time-averaged Cox models were used to estimate death hazard ratios for quarterly averaged nPNA categories controlled for case-mix, comorbidity, dialysis dose, and available markers of malnutrition-inflammation-complex syndrome (MICS). In all patients, both low (<0.6g/kg/day, HR 1.53, [1.47–1.59]) and high nPNA (≥1.4g/kg/day, HR 1.26, [1.19-1.34]) were associated with higher all-cause mortality when compared with the reference (1.0–<1.1g/kg/day). This reverse–J–shape association was also found in sub-analyses performed among racial groups and in hypoalbuminemic patients (Figure). Hence, hypoalbuminemic patients of all races may benefit from higher protein intake, which needs controlled trial to verify